Exact Sciences (EXAS) Cash & Equivalents (2010 - 2025)

Exact Sciences (EXAS) has 16 years of Cash & Equivalents data on file, last reported at $956.0 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $956.0 million, up 59.1% year-over-year; the trailing twelve-month figure through Dec 2025 was $956.0 million (up 59.1% YoY), and the FY2025 annual result was $956.0 million, up 59.1% from the prior year.
• Cash & Equivalents advanced to $956.0 million in Q4 2025 per EXAS's latest filing, from $789.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.1 billion in Q1 2021 and troughed at $11.7 million in Q2 2025.
• A 5-year average of $466.7 million and a median of $392.5 million in 2021 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 183.18% in 2023, then sank 97.79% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $315.5 million in 2021, then slipped by 23.13% to $242.5 million in 2022, then soared by 149.65% to $605.4 million in 2023, then slipped by 0.74% to $600.9 million in 2024, then surged by 59.1% to $956.0 million in 2025.
• Business Quant data shows EXAS's Cash & Equivalents at $956.0 million in Q4 2025, $789.0 million in Q3 2025, and $11.7 million in Q2 2025.